Nephrology, primary care, cardiology, endocrinology: if your patient has kidney disease, hypertension, or cardiorenal risk, there may be a protocol for them here — with study-related care handled by us and every result reported back to you.
SCRI is run by the same board-certified nephrologists who practice at Nephrology Associates, PC. We know what a specialist referral should feel like from your side of the fax machine.
Physician-to-physician updates at screening, enrollment, and closeout. You are never left wondering whether your patient qualified.
Study participation runs alongside their regular care. We manage study-related visits only; you remain their physician.
Study visits, tests, and the investigational therapy are provided at no charge. Insurance is never billed for study-related care.
Every protocol is approved and monitored by an independent Institutional Review Board before a participant is enrolled.
ACRP-certified research coordinators, a dedicated regulatory coordinator, and on-site pharmacy and lab management.
Board-certified nephrologists published in NEJM and leading journals, several serving as medical directors of area dialysis centers.
Send us the clinical picture. We match it against every open protocol, contact the patient with your knowledge, and report the outcome to your office.
Use the form below, call the study team, or fax the clinical summary to (706) 722-5843. Keep identifiers off the web form — fax or phone those.
A coordinator reviews the history against current inclusion criteria and calls the patient to explain the study and answer questions.
Whether the patient enrolls or not, your office hears back directly. Enrolled patients continue seeing you for everything outside the protocol.
Populations are as stated by each sponsor. Final eligibility is confirmed by the study team against the full protocol.
Baxdrostat in combination with dapagliflozin, evaluated for renal outcomes and cardiovascular mortality in chronic kidney disease.
Who it is forAdults with chronic kidney disease and high blood pressure.
Extended TARPEYO® (delayed-release budesonide) treatment in adults with primary IgA nephropathy.
Who it is forAdults with primary IgA nephropathy who have completed 9 months of TARPEYO® 16 mg.
An investigational agent alongside standard of care, evaluated for safety and efficacy in reducing albuminuria.
Who it is forAdults with chronic kidney disease and albuminuria.
Retatrutide's effect on cardiovascular and kidney outcomes in adults living with obesity.
Who it is forAdults living with obesity.
Lepodisiran for cardiovascular risk reduction in participants with high lipoprotein(a).
Who it is forAdults with high lipoprotein(a) who have cardiovascular disease or are at risk of heart attack or stroke.
Broader experience across CKD, diabetic kidney disease, IgA nephropathy, anemia of CKD, ADPKD, resistant hypertension, and dialysis — see the completed-study history.
Clinical context only on this form — no names, dates of birth, or record numbers. We will call your office to coordinate the rest, or you can fax the summary directly.
Tell us a little about your kidney health and we will call you back. It costs nothing to ask.
Start here →We screen against every open protocol and report back to you directly. Your patient stays yours.
Refer now →A site that has delivered kidney trials for more than 25 years, from feasibility to closeout.
Request feasibility →Southeastern Clinical Research Institute, LLC · 1521 Anthony Road, Augusta, Georgia 30904 · (706) 922-3005 · Fax (706) 722-5843